Oyster Point, with AbbVie and Novartis in its sights, wins first FDA approval for nasal spray to treat dry eye disease | Fierce Pharma
Allergan pushes FDA to defend Restasis from early generics | Fierce Pharma
Cyclosporine (Restasis): Basics, Side Effects & Reviews
US Court rejects Teva's lawsuit over generic Restasis
Teva Identifies 'Problem Pattern' Of Complex CRLs Ahead Of GDUFA III :: Generics Bulletin
Cyclosporine (Restasis): Basics, Side Effects & Reviews
FDA Fires Back Over Teva Suit on Restasis 180 Days of Exclusivity | RAPS
August 4, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 563
Allergan and Mohawk tribe ask SCOTUS to review controversial Restasis patent licensing deal | Fierce Pharma
FAQ | RESTASIS®
Restasis Side Effects: Common, Severe, Long Term - Drugs.com
Allergan's much-maligned tribal licensing deal wins reprieve at appeals court | Fierce Pharma
Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease
Patent Docs: FDA Approves Generic Restasis
FDA Approves Vuity, the First Eye Drop to Treat Presbyopia - Eyewire+
Mylan: Did The FDA Clear The Runway For Generic Restasis? (NASDAQ:VTRS) | Seeking Alpha
In a New Twist in Restasis Legal Battle, Teva Sues the FDA
Harrow/Imprimis Fortisite and Iheezo - Eyewire+
FDA Approves First Generic Formulation of Restasis - Eyewire+
Allergan, Inc. v. Teva Pharms.: Federal Court Invalidates Allergan Patents as Obvious - Harvard Journal of Law & Technology
FDA approves first Restasis generic
FDA Approves Restasis Generic for Dry Eye - GoodRx
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA Teva Pharmaceuticals USA, Inc., Plaintiff, v. Alex M. Azar II,
This billion-dollar dry eye drug is behind Allergan's controversial patent deal - MarketWatch
US federal judge invalidates Allergan patents on Restasis - Pharmaceutical Business review
